Prinses Maxima Centrum voor Kinderoncologie B.V. — Sponsor Intelligence | 17 EU Trials

Filter these 17 trials by condition, phase, country and more.

Open in Search →

17 Registered trials

10 Recruiting

1 Completed trials

18 Countries active

41 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase III: 4 Phase II: 4 Phase I/II: 4 Phase I: 2 Phase I (Other): 2 Phase I (FiH): 1

Oversight events:

5 serious breaches 8 temporary halts 1 urgent safety measure across 7 trials

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Neuroblastoma 2 Malignant glioma 1 Brain stem glioma 1 Craniopharyngioma 1 Intracranial germ cell tumour 1 Sepsis 1 Central nervous system neuroblastoma 1 Primitive neuroectodermal tumour 1 Burkitt's lymphoma refractory 1 Inflammatory myofibroblastic tumour 1 Burkitt's lymphoma recurrent 1 Ependymoma 1

Top IMPs

FLUDARABINE PHOSPHATE 3 CYTARABINE 2 ETOPOSIDE 2 HYDROCORTISONE 2 4-((2,4-DIFLUOROPHENYL)METHYL)2,4,6,7,8,9-HEXAHYDRO-7(PHENYLMETHYL)IMIDAZO(1,2-A)PYRIDO(3,4-E)PYRIMIDIN-5(1H)-ONE 1 ANTI-GD2-800CW 1 APREPITANT 1 AUTOLOGOUS CORD BLOOD-DERIVED DENDRITIC CELLS LOADED WITH WT1 PEPTIDE POOL 1 BRIGATINIB 1 CARBOPLATIN 1 CISPLATIN 1 CLOFARABINE 1

All trials

17 total

The PACMAN-Hu19 trial: a phase I/II study with locally produced CD19-targeted CAR T-cell therapy Pending

2023-507597-40-00 Phase I/II 1 country MB-HUCART19.1
PNOC029_Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults Pending

2024-511510-20-00 Phase II 3 countries TOVORAFENIB
The INFLUENCE Trial: Improve CAR T cell therapy by optimizing fludarabine exposure Pending

2025-523096-34-00 Phase III 3 countries FLUDARABINE PHOSPHATE
THRILL: Treat Hyperinflammation in child oncology study Pending

2025-524541-27-00 Phase II 1 country
PNOC023: Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults with Newly Diagnosed or Recurrent Diffuse Mid… Recruiting

2025-521180-13-00 Phase I 1 country 4-((2,4-DIFLUOROPHENYL)METHYL)2,4,6,7,8,9-HEXAHYDRO-7(PHENYLMETHYL)IMIDAZO(1,2-A…
CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit… Recruiting

2023-505000-27-01 Phase II 12 countries QUIZARTINIB DIHYDROCHLORIDE
A phase Ib/II first-in-human imaging study of anti-GD2-800CW in patients with neuroblastoma. Recruiting

2023-507596-22-00 Phase I (FiH) 1 country ANTI-GD2-800CW
VyClo ITCC-092 Recruiting

2023-508050-26-00 Phase I (Other) 6 countries CLOFARABINE; CYTARABINE, DAUNORUBICIN
Ziftomenib in combination with chemotherapy for children with relapsed/refractory acute leukemia Recruiting

2023-505262-28-00 Phase I (Other) 5 countries CYTARABINE; FLUDARABINE PHOSPHATE; HYDROCORTISONE; ZIFTOMENIB
Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastoma Recruiting

2023-509673-22-00 Phase I/II 7 countries CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DINUTUXIMAB BETA; DOXORUB…
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting

2023-504999-25-00 Phase III 12 countries CYTARABINE; DAUNORUBICIN HYDROCHLORIDE; DEXRAZOXANE; ETOPOSIDE; ETOPOSIDE PHOSPH…
68Ga-SATO antagonist in neuroblastoma Recruiting

2024-513843-10-00 Phase I/II 1 country SATOREOTIDE TRIZOXETAN GALLIUM (GA68)
Brigatinib in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors (Briga-PED) Recruiting

2024-513412-10-00 Phase I/II 12 countries BRIGATINIB
Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study) Recruiting

2023-506546-23-00 Phase III 4 countries TEICOPLANIN
A phase I/II post-cord blood HCT dendritic cell vaccination trial directed against WT1 for pediatric and young adult acute myeloid leukemia:… Halted

2024-517922-24-00 Phase I 1 country AUTOLOGOUS CORD BLOOD-DERIVED DENDRITIC CELLS LOADED WITH WT1 PEPTIDE POOL
PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) inc… Halted

2023-507598-16-00 Phase II 1 country DORDAVIPRONE; PAXALISIB
DAVINCY trial: optimal Duration of (fos)Aprepitant prophylaxis for nausea and Vomiting INduced by ChemotherapY in children: a double-blind p… Ended

2024-517846-32-00 Phase III 1 country APREPITANT; FOSAPREPITANT

Showing 1–17 of 17 trials

← All sponsors A–Z